Crescent Biopharma, Inc. (CBIO) income statement
CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$12.40−0.64 (-4.91%)
Close on Nov 18, 2026Market cap $460.59MP/E –Yield –
Crescent Biopharma, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -1553.6%
- Net margin
- -885.5%
- Return on equity, FY2025
- -164.2%
Financial strength
- Current ratio
- 9.66
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 925.7%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.82
- Dividend yield
- –
See a number that looks wrong?